SCHEMBL935807

SCHEMBL935807

CNC(=O)C(O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)nc(Cl)nc32)[C@H](O)[C@@H]1O

nearest known ligand 0.78

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 18/20 0.78
ADORA1 P30542 7/20 0.78
ADORA2A P29274 5/20 0.78
HTR2C P28335 1/20 0.78
PPARG P37231 1/20 0.78
HTR2B P41595 1/20 0.78
PPARD Q03181 1/20 0.78
ABCG2 Q9UNQ0 1/20 0.78
TP53 P04637 1/20 0.78
CYP1A2 P05177 1/20 0.78
MAPT P10636 1/20 0.78
MAPK1 P28482 1/20 0.78
ADORA2B P29275 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29464001 1.00 ADORA3 (0.78) ADORA3ADORA1ADORA2AHTR2CPPARG
SCHEMBL935056 1.00 ADORA3 (0.78) ADORA3ADORA1ADORA2AHTR2CPPARG
SCHEMBL8983111 0.89 ADORA3 (0.75) ADORA3ADORA1ADORA2AHTR2CPPARG
SCHEMBL29463995 0.89 ADORA3 (0.77) ADORA3ADORA1ADORA2AHTR2CHTR2B
SCHEMBL25396739 0.88 ADORA3 (0.73) ADORA3ADORA1ADORA2AHTR2CPPARG
SCHEMBL7287853 0.88 ADORA3 (0.73) ADORA3ADORA1ADORA2AHTR2CPPARG
Namodenoson SCHEMBL1170028 0.88 ADORA3 (1.00) ADORA3ADORA1ADORA2AHTR2CPPARG
Namodenoson SCHEMBL15148066 0.88 ADORA3 (1.00) ADORA3ADORA1ADORA2AHTR2CPPARG
Namodenoson SCHEMBL29376760 0.88 ADORA3 (1.00) ADORA3ADORA1ADORA2AHTR2CPPARG
Namodenoson SCHEMBL15150531 0.88 ADORA3 (1.00) ADORA3ADORA1ADORA2AHTR2CPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299032-A1 Method and Composition for Thickening Hair SHISEIDO COMPANY, LTD. (JP) 2007-12-27 US claimed
EP-1683509-A1 METHOD AND COMPOSITION FOR HAIR THICKENING SHISEIDO COMPANY, LTD. (JP) 2006-07-26 EP claimed
US-11969501-B2 Auris formulations for treating otic diseases and conditions DOMPÉ FARMACEUTICI S.P.A. (IT) 2024-04-30 US disclosed
US-11918653-B2 Triglyceride otic formulations and uses thereof DOMPÉ FARMACEUTICI S.P.A. (IT) 2024-03-05 US disclosed
US-20220040096-A1 AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS OTONOMY INC (US) 2022-02-10 US disclosed
US-11123286-B2 Auris formulations for treating otic diseases and conditions OTONOMY, INC. (US) 2021-09-21 US disclosed
US-11123285-B2 Auris formulations for treating OTIC diseases and conditions OTONOMY, INC. (US) 2021-09-21 US disclosed
US-20210138069-A1 TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF DOMPÉ FARMACEUTICI S.P.A. (IT) 2021-05-13 US disclosed
US-20200397907-A1 TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF OTONOMY, INC. 2020-12-24 US disclosed
US-10821185-B2 Triglyceride otic formulations and uses thereof OTONOMY INC. (US) 2020-11-03 US disclosed
US-10751281-B2 Auris formulations for treating otic diseases and conditions OTONOMY, INC. (US) 2020-08-25 US disclosed
EP-2490722-A2 MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS Otonomy, Inc. (US) 2012-08-29 EP disclosed
EP-2456419-A1 A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION Oradin Pharmaceutical Ltd. (IL) 2012-05-30 EP disclosed
WO-2011049960-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS OTONOMY, INC. (US) 2011-04-28 WO disclosed
WO-2011050206-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS OTONOMY, INC. (US) 2011-04-28 WO disclosed
WO-2011049958-A2 MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS OTONOMY, INC. (US) 2011-04-28 WO disclosed
WO-2011010306-A1 A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2011-01-27 WO disclosed
US-20090306225-A1 AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS OTONOMY, INC. (US) 2009-12-10 US disclosed
US-20070299032-A1 Method and Composition for Thickening Hair SHISEIDO COMPANY, LTD. (JP) 2007-12-27 US disclosed
EP-1683509-A1 METHOD AND COMPOSITION FOR HAIR THICKENING SHISEIDO COMPANY, LTD. (JP) 2006-07-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210138069-A1 TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF CETP, LIPA, APOB ADORA3 2478/4885ADORA1 2255/4885ADORA2A 2398/4885
US-20220040096-A1 AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS OTC, AQP4, SLC26A4 ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885
US-11123286-B2 Auris formulations for treating otic diseases and conditions OTC, AQP4, SLC26A4 ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885
US-10751281-B2 Auris formulations for treating otic diseases and conditions OTC, AQP4, SLC26A4 ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885
US-10821185-B2 Triglyceride otic formulations and uses thereof CETP, LIPA, APOB ADORA3 2382/4885ADORA1 2143/4885ADORA2A 2246/4885
US-20090306225-A1 AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS OTC, AQP4, SLC26A4 ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885
US-11123285-B2 Auris formulations for treating OTIC diseases and conditions OTC, AQP4, SLC26A4 ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885
US-11918653-B2 Triglyceride otic formulations and uses thereof CETP, LIPA, APOB ADORA3 2478/4885ADORA1 2255/4885ADORA2A 2398/4885
US-20200397907-A1 TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF CETP, LIPA, APOB ADORA3 2382/4885ADORA1 2143/4885ADORA2A 2246/4885
US-11969501-B2 Auris formulations for treating otic diseases and conditions OTC, AQP4, SLC26A4 ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.